VITRAKVI

Larotrectinib 20mg/1mL, Oral solution

Grapefruit juice

· Severity: Major

· Notes for Consumers: Do not eat grapefruit or drink grapefruit juice while taking Larotrectinib. Grapefruit can increase the amount of Larotrectinib in your blood and increase the risk of side effects from Larotrectinib including tiredness, nausea, vomiting, dizziness, cough, constipation, diarrhea, dark yellow or brown urine, general ill feeling or flu-like symptoms, light-colored stools, right upper belly pain, or yellowing of the eyes or skin.

· Notes for Professionals: Advise patients to avoid grapefruit or grapefruit juice while taking larotrectinib. Coadministration may increase larotrectinib exposure resulting in treatment-related adverse effects. Larotrectinib is a CYP3A4 substrate; grapefruit is a strong CYP3A4 inhibitor. Coadministration of a strong CYP3A4 inhibitor increased the AUC of larotrectinib by 4.3-fold in a drug interaction study.

<b>DISCLAIMER:</b><em> This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.</em>